Abstract: Early blood-brain barrier (BBB) disturbance contributes to many different neurological diseases including Alzheimer’s disease, Parkinson’s disease and stroke, particularly in the etiology and early stages (Abbott et al., 2010). Although supporting barrier function is a potential strategy to radically improve treatment efficacy and disease outcome, ways to achieve this objective remain elusive. Being a sophisticated system consisting of multicellular interactions, better understanding of how individual cell-specific molecular and metabolic changes modulate the unit responses would provide significant insight. In this regard, we have generated severity-related metabolomic databases to reveal fundamental BBB cell-specific processes likely to occur physiologically and during disease (Huang et al., 2020a). This resource provides new opportunities for future clinical applications.